

# Seijii Fukumoto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8909294/seijii-fukumoto-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198  
papers

16,219  
citations

60  
h-index

125  
g-index

263  
ext. papers

17,854  
ext. citations

5.5  
avg, IF

6.42  
L-index

#	Paper	IF	Citations
198	Phosphate-Sensing.. <i>Advances in Experimental Medicine and Biology</i> , <b>2022</b> , 1362, 27-35	3.6	0
197	FGF23 and Hypophosphatemic Rickets/Osteomalacia. <i>Current Osteoporosis Reports</i> , <b>2021</b> , 19, 669	5.4	2
196	Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.. <i>Bone Reports</i> , <b>2021</b> , 15, 101144	2.6	1
195	Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e3682-e3692	5.6	3
194	Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. <i>Calcified Tissue International</i> , <b>2021</b> , 108, 104-115	3.9	4
193	Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 262-270	6.3	21
192	FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. <i>Journal of Molecular Endocrinology</i> , <b>2021</b> , 66, R57-R65	4.5	16
191	Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. <i>Journal of Bone and Mineral Metabolism</i> , <b>2021</b> , 39, 1066-1075	2.9	3
190	Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span. <i>Biochemistry and Biophysics Reports</i> , <b>2021</b> , 27, 101107	2.2	2
189	Klotho: the discovery of the FGF23 coreceptor <b>2021</b> , 225-231		
188	Transcriptional Regulation of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1) by Calcemic Factors in Keratinocytes.. <i>Journal of Nutritional Science and Vitaminology</i> , <b>2021</b> , 67, 424-428	1.1	1
187	Fibroblast growth factor receptor as a potential candidate for phosphate sensing. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2020</b> , 29, 446-452	3.5	7
186	Phosphate-sensing and regulatory mechanism of FGF23 production. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 877-883	5.2	20
185	Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. <i>BMJ Open</i> , <b>2020</b> , 10, e036367	3	0
184	Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 687-694	2.9	2
183	Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle. <i>Journal of Molecular Endocrinology</i> , <b>2020</b> , 64, 195-208	4.5	4
182	Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 141-144	2.9	4

181	The Bone-IGF23-Klotho Axis and Associated Diseases <b>2020</b> , 540-550		
180	Fibroblast growth factor 23 <b>2020</b> , 1529-1538		1
179	Approach to patients with hypophosphataemia. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 163-174	18.1	22
178	How do we sense phosphate to regulate serum phosphate level?. <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 1-6	2.9	2
177	FGF23 and Bone and Mineral Metabolism. <i>Handbook of Experimental Pharmacology</i> , <b>2020</b> , 262, 281-308	3.2	8
176	Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 70-77	2.9	12
175	Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature. <i>Calcified Tissue International</i> , <b>2019</b> , 105, 476-486	3.9	6
174	Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11418-11427	11.5	59
173	Phosphate Metabolism, Hyperphosphatemia, and Hypophosphatemia <b>2019</b> , 68-74		
172	Persistent Activation of Calcium-Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength. <i>JBMR Plus</i> , <b>2019</b> , 3, e10182	3.9	1
171	Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. <i>EBioMedicine</i> , <b>2019</b> , 45, 630-645	8.8	34
170	Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO). <i>Bone Reports</i> , <b>2019</b> , 10, 100192	2.6	9
169	Development of versatile non-homologous end joining-based knock-in module for genome editing. <i>Scientific Reports</i> , <b>2018</b> , 8, 593	4.9	19
168	X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. <i>Endocrine Reviews</i> , <b>2018</b> , 39, 274-291	27.2	57
167	Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 48	5.7	20
166	Incidence rate and characteristics of symptomatic vitamin D deficiency in children: a nationwide survey in Japan. <i>Endocrine Journal</i> , <b>2018</b> , 65, 593-599	2.9	7
165	FGF23 beyond Phosphotropic Hormone. <i>Trends in Endocrinology and Metabolism</i> , <b>2018</b> , 29, 755-767	8.8	28
164	Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones. <i>Computer Assisted Surgery</i> , <b>2017</b> , 22, 14-19	1.8	12

163	Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23. <i>Endocrine Journal</i> , <b>2017</b> , 64, 1033-1039	2.9	11
162	Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A. <i>Endocrine Journal</i> , <b>2017</b> , 64, 589-596	2.9	3
161	Tumor-induced Osteomalacia Caused by a Parotid Tumor. <i>Internal Medicine</i> , <b>2017</b> , 56, 535-539	1.1	5
160	Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review. <i>Internal Medicine</i> , <b>2017</b> , 56, 2455-2461	1.1	1
159	Assessment criteria for vitamin D deficiency/insufficiency in Japan - proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. <i>Endocrine Journal</i> , <b>2017</b> , 64, 1-6	2.9	28
158	Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. <i>International Orthopaedics</i> , <b>2017</b> , 41, 2597-2603	3.8	8
157	Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions. <i>Scientific Reports</i> , <b>2017</b> , 7, 7786	4.9	20
156	Tumour-induced osteomalacia. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17044	51.1	130
155	Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. <i>Endocrine Research</i> , <b>2017</b> , 42, 132-137	1.9	41
154	Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. <i>Journal of Bone and Mineral Metabolism</i> , <b>2017</b> , 35, 1-5	2.9	52
153	Recent advances in the management of osteoporosis. <i>F1000Research</i> , <b>2017</b> , 6, 625	3.6	22
152	ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors. <i>Medical Molecular Morphology</i> , <b>2016</b> , 49, 203-209	2.3	12
151	FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism. <i>Calcified Tissue International</i> , <b>2016</b> , 98, 334-40	3.9	34
150	Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. <i>Journal of Bone and Mineral Metabolism</i> , <b>2016</b> , 34, 132-9	2.9	41
149	High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. <i>Endocrine Journal</i> , <b>2016</b> , 63, 479-84	2.9	18
148	Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors. <i>Endocrine Journal</i> , <b>2016</b> , 63, 397-404	2.9	6
147	FGF23-Klotho axis in CKD. <i>Renal Replacement Therapy</i> , <b>2016</b> , 2,	2.3	4
146	Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer. <i>Internal Medicine</i> , <b>2016</b> , 55, 3623-3626	1.1	2

145	Oncogenic osteomalacia caused by an occult paranasal sinus tumor. <i>Auris Nasus Larynx</i> , <b>2015</b> , 42, 167-9	2.2	11
144	Pathogenesis and diagnostic criteria for rickets and osteomalacia--proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. <i>Journal of Bone and Mineral Metabolism</i> , <b>2015</b> , 33, 467-73	2.9	30
143	Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. <i>Journal of Orthopaedic Science</i> , <b>2015</b> , 20, 765-71	1.6	9
142	Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. <i>Endocrine Journal</i> , <b>2015</b> , 62, 811-6	2.9	73
141	Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. <i>Endocrine Journal</i> , <b>2015</b> , 62, 665-71	2.9	23
140	Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor. <i>Internal Medicine</i> , <b>2015</b> , 54, 2201-5	1.1	1
139	Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH). <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 1980-93	6.3	40
138	Phosphate metabolism and vitamin D. <i>BoneKEy Reports</i> , <b>2014</b> , 3, 497		82
137	Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E363-8	5.6	23
136	Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. <i>Kidney International</i> , <b>2014</b> , 85, 1103-11	9.9	123
135	What can FGF23 do without Klotho?. <i>BoneKEy Reports</i> , <b>2014</b> , 3, 551		1
134	Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. <i>Bone</i> , <b>2014</b> , 67, 56-62	4.7	50
133	Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia. <i>Bone</i> , <b>2014</b> , 67, 145-51	4.7	21
132	Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation. <i>Journal of Bone and Mineral Metabolism</i> , <b>2014</b> , 32, 393-9	2.9	16
131	Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia. <i>Endocrinology and Metabolism</i> , <b>2014</b> , 29, 136-43	3.5	26
130	Anti-fibroblast growth factor 23 antibody therapy. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2014</b> , 23, 346-51	3.5	18
129	Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. <i>Therapeutic Apheresis and Dialysis</i> , <b>2013</b> , 17, 247-88	1.9	220
128	Clinical Aspects of Fibroblast Growth Factor 23 <b>2013</b> , 151-166		

127	Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 67-76	5.6	19
126	Evaluation of a new automated chemiluminescence immunoassay for FGF23. <i>Journal of Bone and Mineral Metabolism</i> , <b>2012</b> , 30, 217-21	2.9	27
125	Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. <i>Internal Medicine</i> , <b>2012</b> , 51, 2375-8	1.1	24
124	FGF23 as a novel therapeutic target. <i>Advances in Experimental Medicine and Biology</i> , <b>2012</b> , 728, 158-70	3.6	9
123	Mutational analysis of patients with FGF23-related hypophosphatemic rickets. <i>European Journal of Endocrinology</i> , <b>2012</b> , 167, 165-72	6.5	19
122	What's new in FGF23 research?. <i>BoneKEy Reports</i> , <b>2012</b> , 1, 111		2
121	Kidney transplantation restored uncoupled bone turnover in end-stage renal disease. <i>Clinical Nephrology</i> , <b>2012</b> , 78, 10-6	2.1	3
120	A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. <i>Bone</i> , <b>2011</b> , 49, 913-6	4.7	54
119	Osteomalacia caused by skull base tumors: report of 2 cases. <i>Neurosurgery</i> , <b>2011</b> , 69, E239-44; discussion E244	3.2	12
118	Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. <i>Therapeutic Apheresis and Dialysis</i> , <b>2011</b> , 15, 481-7	1.9	16
117	Fibroblast growth factor 23 as a phosphotropic hormone and beyond. <i>Journal of Bone and Mineral Metabolism</i> , <b>2011</b> , 29, 507-14	2.9	36
116	Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 803-10	6.3	84
115	Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. <i>Endocrinology</i> , <b>2011</b> , 152, 4-10	4.8	68
114	The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 2691-5	4.3	26
113	Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. <i>Journal of Internal Medicine</i> , <b>2010</b> , 268, 390-4	10.8	38
112	Runx1 and Runx2 cooperate during sternal morphogenesis. <i>Development (Cambridge)</i> , <b>2010</b> , 137, 1159-67	6	68
111	FGF23: Phosphate metabolism and beyond. <i>IBMS BoneKEy</i> , <b>2010</b> , 7, 268-278		9
110	Phosphate metabolism: Meeting report from the 32nd annual meeting of the American Society for bone and mineral research October 15-19, 2010 in Toronto, Ontario, Canada. <i>IBMS BoneKEy</i> , <b>2010</b> , 7, 469-472		

109	Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , <b>2010</b> , 109, e57-63		24
108	Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. <i>Kidney International</i> , <b>2010</b> , 78, 975-80	9.9	243
107	Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis. <i>Endocrine Journal</i> , <b>2010</b> , 57, 485-92	2.9	45
106	Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. <i>European Journal of Endocrinology</i> , <b>2009</b> , 161, 647-51	6.5	25
105	A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism. <i>Journal of Bone and Mineral Metabolism</i> , <b>2009</b> , 27, 386-9	2.9	10
104	Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1879-88	6.3	193
103	Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. <i>Bone</i> , <b>2009</b> , 45, 814-6	4.7	101
102	Bone as an endocrine organ. <i>Trends in Endocrinology and Metabolism</i> , <b>2009</b> , 20, 230-6	8.8	218
101	The role of bone in phosphate metabolism. <i>Molecular and Cellular Endocrinology</i> , <b>2009</b> , 310, 63-70	4.4	20
100	A microRNA regulatory mechanism of osteoblast differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 20794-9	11.5	241
99	Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. <i>International Journal of Pediatric Endocrinology (Springer)</i> , <b>2009</b> , 2009, 496514	1.5	20
98	Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. <i>International Journal of Pediatric Endocrinology (Springer)</i> , <b>2009</b> , 2009, 496514	1.5	32
97	Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. <i>Bone</i> , <b>2008</b> , 42, 1235-9	4.7	155
96	Causes and differential diagnosis of hypocalcemia--recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan. <i>Endocrine Journal</i> , <b>2008</b> , 55, 787-94	2.9	18
95	Actions and mode of actions of FGF19 subfamily members. <i>Endocrine Journal</i> , <b>2008</b> , 55, 23-31	2.9	100
94	Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23. <i>Internal Medicine</i> , <b>2008</b> , 47, 337-43	1.1	83
93	Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. <i>Internal Medicine</i> , <b>2008</b> , 47, 957-61	1.1	34
92	Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. <i>Internal Medicine</i> , <b>2008</b> , 47, 637-41	1.1	28

91	The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: findings in murine models and in human disease. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2764-75		42
90	Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1509-18	6.3	157
89	Central control of bone remodeling by neuromedin U. <i>Nature Medicine</i> , <b>2007</b> , 13, 1234-40	50.5	151
88	Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. <i>Clinical and Experimental Nephrology</i> , <b>2007</b> , 11, 255-257	2.5	10
87	Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. <i>Journal of Bone and Mineral Metabolism</i> , <b>2007</b> , 25, 419-22	2.9	107
86	Fibroblast growth factor (FGF)23 in patients with acromegaly. <i>Endocrine Journal</i> , <b>2007</b> , 54, 481-4	2.9	20
85	Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. <i>Endocrine Journal</i> , <b>2007</b> , 54, 465-70	2.9	24
84	FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. <i>Bone</i> , <b>2007</b> , 40, 1190-5	4.7	111
83	Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 235-42	6.3	126
82	Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. <i>Journal of Cellular Biochemistry</i> , <b>2006</b> , 99, 196-208	4.7	224
81	An instructive case suggesting cyclical primary hyperparathyroidism. <i>Endocrine Journal</i> , <b>2006</b> , 53, 311-6	2.9	4
80	Klotho converts canonical FGF receptor into a specific receptor for FGF23. <i>Nature</i> , <b>2006</b> , 444, 770-4	50.4	1405
79	Ghrelin directly regulates bone formation. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 790-8	6.3	219
78	Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. <i>Kidney International</i> , <b>2005</b> , 67, 1120-5	9.9	97
77	Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. <i>Kidney International</i> , <b>2005</b> , 67, 1171-8	9.9	153
76	Post-translational modification of Fibroblast Growth Factor 23. <i>Therapeutic Apheresis and Dialysis</i> , <b>2005</b> , 9, 319-22	1.9	29
75	Comparison of two assays for fibroblast growth factor (FGF)-23. <i>Journal of Bone and Mineral Metabolism</i> , <b>2005</b> , 23, 435-40	2.9	70
74	Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. <i>American Journal of Physiology - Renal Physiology</i> , <b>2005</b> , 289, F1088-95	4.3	272



73	A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 5523-7	5.6	181
72	Fibroblast growth factor-23 in patients with Graves disease before and after antithyroid therapy: its important role in serum phosphate regulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 4211-5	5.6	25
71	Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. <i>Nephron Clinical Practice</i> , <b>2005</b> , 101, c94-9		88
70	Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3979-82	5.6	139
69	Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. <i>European Journal of Endocrinology</i> , <b>2004</b> , 151, 55-60	6.5	59
68	Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 44, 250-6	7.4	272
67	FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 429-35	6.3	1276
66	FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 314, 409-14	7.4	345
65	Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 561-568	15.9	1089
64	Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 561-8	15.9	565
63	A family of autosomal dominant hypocalcemia with an activating mutation of calcium-sensing receptor gene. <i>Endocrine Journal</i> , <b>2003</b> , 50, 91-6	2.9	15
62	Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 827-35	6.3	74
61	Decreased AP-1 activity and interleukin-11 expression by bone marrow stromal cells may be associated with impaired bone formation in aged mice. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 1461-70	6.3	25
60	Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. <i>Journal of Bone and Mineral Metabolism</i> , <b>2003</b> , 21, 166-71	2.9	49
59	Stimulation of Smad1 transcriptional activity by Ras-extracellular signal-regulated kinase pathway: a possible mechanism for collagen-dependent osteoblastic differentiation. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17, 240-8	6.3	69
58	Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17, 753-7	6.3	4
57	Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. <i>Endocrinology</i> , <b>2002</b> , 143, 3179-82	4.8	348
56	A family of autosomal dominant hypocalcemia with a positive correlation between serum calcium and magnesium: identification of a novel gain of function mutation (Ser(820)Phe) in the calcium-sensing receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 2681-7	5.6	21

55	Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 49011-8	5.4	108
54	Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2002</b> , 11, 385-9	3.5	60
53	Marked hypercalcemia in a patient with hypocalciuric hypercalcemia without a mutation in the calcium-sensing receptor gene. <i>Internal Medicine</i> , <b>2002</b> , 41, 1153-7	1.1	1
52	Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro. <i>Endocrine Journal</i> , <b>2002</b> , 49, 439-47	2.9	14
51	Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 4957-60	5.6	555
50	Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. <i>Lancet, The</i> , <b>2002</b> , 360, 692-4	4.0	324
49	Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia. <i>Endocrine Journal</i> , <b>2001</b> , 48, 603-10	2.9	8
48	Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo. <i>Journal of Bone and Mineral Metabolism</i> , <b>2001</b> , 19, 207-12	2.9	17
47	Focal adhesion kinase activity is required for bone morphogenetic protein--Smad1 signaling and osteoblastic differentiation in murine MC3T3-E1 cells. <i>Journal of Bone and Mineral Research</i> , <b>2001</b> , 16, 1772-9	6.3	89
46	GH inhibits interferon-gamma-induced signal transducer and activator of transcription-1 activation and expression of the inducible isoform of nitric oxide synthase in INS-1 cells. <i>Endocrinology</i> , <b>2001</b> , 142, 3909-16	4.8	11
45	Effects of 1-year treatment with fluvastatin or pravastatin on bone. <i>American Journal of Medicine</i> , <b>2001</b> , 110, 584-7	2.4	41
44	Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 6500-5	11.5	1164
43	Inactivating mutations of calcium-sensing receptor results in parathyroid lipohyperplasia. <i>Diagnostic Molecular Pathology</i> , <b>2001</b> , 10, 242-7		28
42	Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 7553-7	5.4	63
41	Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 267, 632-7	3.4	85
40	Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. <i>Bone</i> , <b>2000</b> , 27, 769-76	4.7	64
39	No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 4111-7	5.6	65
38	Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. <i>Endocrinology</i> , <b>1999</b> , 140, 5060-5	4.8	88

37	Heterozygous <i>gsp</i> mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone. <i>Endocrinology</i> , <b>1999</b> , 140, 2018-26	4.8	13
36	Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. <i>Endocrinology</i> , <b>1999</b> , 140, 1005-8	4.8	147
35	A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 363-6	5.6	54
34	An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. <i>Clinical Endocrinology</i> , <b>1999</b> , 50, 537-43	3.4	49
33	Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. <i>Bone</i> , <b>1999</b> , 25, 375-7	4.7	64
32	Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. <i>Endocrinology</i> , <b>1999</b> , 140, 2125-33	4.8	126
31	Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. <i>Endocrine Journal</i> , <b>1999</b> , 46, 795-801	2.9	50
30	A Novel Activating Mutation in Calcium-Sensing Receptor Gene Associated with a Family of Autosomal Dominant Hypocalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 363-366	5.6	48
29	No Enzyme Activity of 25-Hydroxyvitamin D3 1 $\beta$ -Hydroxylase Gene Product in Pseudovitamin D Deficiency Rickets, Including That with Mild Clinical Manifestation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 4111-4117	5.6	62
28	Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 1370-7	6.3	66
27	Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene: absence of mutation in patients with pseudohypoparathyroidism type Ib. <i>Molecular and Cellular Endocrinology</i> , <b>1998</b> , 141, 41-7	4.4	14
26	Effect of mechanical unloading and reloading on periosteal bone formation and gene expression in tail-suspended rapidly growing rats. <i>Bone</i> , <b>1998</b> , 22, 89S-93S	4.7	54
25	Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 2915-20	5.6	108
24	A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. <i>Journal of Bone and Mineral Research</i> , <b>1997</b> , 12, 590-7	6.3	12
23	Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. <i>Journal of Bone and Mineral Research</i> , <b>1997</b> , 12, 1058-67	6.3	57
22	Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 2915-2920	5.6	87
21	Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 607-611	5.6	56
20	Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 2554-2558	5.6	53

19	Assay of serum pyridinoline: a potential marker for bone resorption. <i>Clinica Chimica Acta</i> , <b>1995</b> , 235, 221-226	7.2	13
18	Relationship between actions of transforming growth factor (TGF)-beta and cell surface expression of its receptors in clonal osteoblastic cells. <i>Journal of Cellular Physiology</i> , <b>1995</b> , 162, 315-21	7	41
17	Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1994</b> , 1201, 223-84	4	19
16	Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1994</b> , 79, 165-170	5.6	12
15	Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?. <i>Molecular and Cellular Endocrinology</i> , <b>1993</b> , 92, 55-62	4.4	80
14	Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?. <i>Molecular and Cellular Endocrinology</i> , <b>1993</b> , 94, 145	4.4	3
13	Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. <i>Journal of Cellular Physiology</i> , <b>1992</b> , 152, 346-55	7	34
12	Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. <i>Journal of Cellular Physiology</i> , <b>1991</b> , 149, 34-43	7	51
11	Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1991</b> , 73, 877-81	5.6	54
10	Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. <i>Annals of Internal Medicine</i> , <b>1989</b> , 111, 484-8	8	67
9	Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production. <i>Endocrinology</i> , <b>1989</b> , 124, 2057-62	4.8	45
8	Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3. <i>Endocrinology</i> , <b>1989</b> , 124, 511-7	4.8	19
7	Usefulness of Nude Rats in Studies on Characteristics of Human Cancers <b>1989</b> , 220-226		
6	A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy. <i>Calcified Tissue International</i> , <b>1988</b> , 43, 97-102	3.9	22
5	Expression of parathyroid hormone-related protein in a human T cell lymphotropic virus type I-infected T cell line. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 154, 1182-8	3.4	58
4	Clinical Evaluation of Calcium Metabolism in Adult T-Cell Leukemia/Lymphoma. <i>Archives of Internal Medicine</i> , <b>1988</b> , 148, 921		49
3	Renal magnesium wasting in a patient with short bowel syndrome with magnesium deficiency: effect of 1 alpha-hydroxyvitamin D3 treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1987</b> , 65, 1301-4	5.6	16
2	Stimulation of Osteoclast Formation by 1,25-Dihydroxyvitamin D Requires Its Binding to Vitamin D Receptor (VDR) in Osteoblastic Cells: Studies Using VDR Knockout Mice		39

- 1 Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo 112